$60.33
0.07% yesterday
NYSE, Sep 27, 10:10 pm CET
ISIN
US1488061029
Symbol
CTLT
Sector
Industry

Catalent Inc Stock price

$60.33
+0.93 1.57% 1M
+3.85 6.82% 6M
+15.40 34.28% YTD
+14.55 31.78% 1Y
-76.06 55.77% 3Y
+12.88 27.14% 5Y
+35.16 139.69% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.04 0.07%
ISIN
US1488061029
Symbol
CTLT
Sector
Industry

Key metrics

Market capitalization $10.94b
Enterprise Value $15.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.57
P/S ratio (TTM) P/S ratio 2.50
P/B ratio (TTM) P/B ratio 3.03
Revenue growth (TTM) Revenue growth 2.46%
Revenue (TTM) Revenue $4.38b
EBIT (operating result TTM) EBIT $145.00m
Free Cash Flow (TTM) Free Cash Flow $-59.00m
Cash position $289.00m
EPS (TTM) EPS $-5.75
P/E forward negative
P/S forward 2.33
EV/Sales forward 3.34
Short interest 6.42%
Show more

Is Catalent Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Catalent Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Catalent Inc forecast:

8x Hold
89%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a Catalent Inc forecast:

Hold
89%
Sell
11%

Financial data from Catalent Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
4,381 4,381
2% 2%
100%
- Direct Costs 3,428 3,428
7% 7%
78%
953 953
10% 10%
22%
- Selling and Administrative Expenses 302 302
14% 14%
7%
- Research and Development Expense 17 17
-
0%
634 634
6% 6%
14%
- Depreciation and Amortization 489 489
16% 16%
11%
EBIT (Operating Income) EBIT 145 145
43% 43%
3%
Net Profit -1,043 -1,043
350% 350%
-24%

In millions USD.

Don't miss a Thing! We will send you all news about Catalent Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalent Inc Stock News

Negative
Reuters
28 days ago
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
Positive
Reuters
30 days ago
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
Neutral
Business Wire
30 days ago
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the fourth quarter of fiscal 2024, which ended June 30, 2024. “I am pleased to report that Catalent ended our fiscal 2024 in a strong position, including growing non-COVID revenue by nearly 30% in the f...
More Catalent Inc News

Company Profile

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.

Head office United States
CEO Alessandro Maselli
Employees 16,900
Founded 1933
Website www.catalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today